Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.46
-0.0100-0.68%
Post-market: 1.45-0.0102-0.70%18:43 EDT
Volume:551.09K
Turnover:806.66K
Market Cap:19.36M
PE:-1.46
High:1.50
Open:1.46
Low:1.44
Close:1.47
52wk High:3.80
52wk Low:0.6506
Shares:13.26M
Float Shares:13.19M
Volume Ratio:0.10
T/O Rate:4.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9971
EPS(LYR):-1.2844
ROE:-104.87%
ROA:-62.11%
PB:1.99
PE(LYR):-1.14

Loading ...

Hoth Therapeutics Announces 100% Response Rate in Phase 2a Trial for HT-001, Targeting EGFR Inhibitor-Induced Skin Toxicities

Reuters
·
Jun 24

Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities

Reuters
·
Jun 23

Hoth Therapeutics Regains Nasdaq Compliance, Clears Key Listing Hurdle

Reuters
·
Jun 19

Hoth Therapeutics Announces Positive Preclinical Safety Data for Cancer-Fighting HT-KIT, Paving Way for IND Filing

Reuters
·
Jun 18

Hoth Therapeutics Inc. to Attend BIO International Convention in Boston

Reuters
·
Jun 16

Hoth Therapeutics Secures Japanese Patent for Innovative HT-KIT Platform Targeting Mast Cell Diseases

Reuters
·
Jun 12

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jun 12

Hoth Therapeutics Inc. Advances HT-001 with Expanded Access Program Application to Address Severe Skin Toxicities in Cancer Patients

Reuters
·
Jun 11

Hoth Therapeutics Secures New Patent Filing for Innovative HT-001 Formulation, Strengthening IP Portfolio in Cancer Care

Reuters
·
Jun 05

Hoth Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Christopher Michael Camarra

Reuters
·
May 22

Hoth Therapeutics Inc. Faces Nasdaq Non-Compliance for Minimum Bid Price Requirement

Reuters
·
May 17

Hoth Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Hoth Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 10

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 15

BRIEF-Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial

Reuters
·
Apr 15